Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study Assessing Efficacy and Safety of a 12 Week Treatment With BI 54903 Administered at 90.9 Mcg b.i.d. and 181.8 Mcg q.d. (p.m.Dosing) Via Respimat® Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

NCT01458886 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01458886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01458886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study Assessing Efficacy and Safety of a 12 Week Treatment With BI 54903 Administered at 90.9 Mcg b.i.d. and 181.8 Mcg q.d. (p.m.Dosing) Via Respimat® Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2011
Completion date
Not reported
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

asthma